A precision medicine approach to Alzheimer’s disease

By integrating information from a large dataset in patients tested with the active molecule tramiprosate, genetic markers and new insights into the pathology of Alzheimer’s disease (AD), we have identified a group of patients that are likely to have substantial benefit from tramiprosate. We have also created ALZ-801, an optimized prodrug of tramiprosate that improves the tolerability profile.  ALZ-801 is one of the few oral drug candidates in advanced stages of clinical testing in AD, a pill with a favorable safety profile and the potential to modify an underlying cause of the disease.

About ALZ-801

Press Releases

In the news

Load More